Nº 6 (2012)

The article analyzes data of domestic and foreign literature devoted to the problem of coronaritis in patients with rheumatic diseases. The significance of atherosclerosis and its complications in rheumatic diseases, as well as methods of diagnosis and treatment in these patients are discussed.

The article presents the results of the combined treatment of patients with dorsopathies accompanied by pain and muscular-tonic syndromes. Evaluation of clinical efficacy of neurotropic complex Milgamma in monotherapy and in combined therapy with nonsteroidal anti-inflammatory drugs was performed.

Diabetic autonomic neuropathy (DAN) is a common complication of diabetes affecting negatively both on survival and quality of life of patients with diabetes mellitus. Based on testing of vegetative status, the prevalence of DAN varies from 7.7 to 90%. DAN may affect all organs and systems, or only some of them. A series of tests, including, in particular, evaluation of cardiovascular reflexes, are used for the diagnosis of DAN. In the treatment of DAN, administration of thiamine-containing drugs, such as Trigamma, is reasonable.

The article discusses the problem of modern therapeutic tactics in the treatment of rheumatoid arthritis (RA), a one of the most serious human diseases. The practice in the early application of the disease-modifying anti-rheumatic drugs (DMARDs) for improvement of long-term outcomes of the disease, which became possible after the development of new diagnostic criteria EULAR / ACR (2010) for RA is considered. International recommendations for management of patients with early arthritis and for the treatment strategies for RA are presented. Particular attention is given to a new class of drugs for the treatment of RA - genetically engineered biological substances that have an impact on the various links of the pathogenesis of the disease directly in the synovium and are used in combination therapy with DMARDs, particularly methotrexate. Thus, improvement of long-term outcomes of RA depends on the timely diagnosis of the disease, early treatment with DMARDs, appropriate assessment of the significance of symptomatic therapy, and tight control of the results of therapy with the timely correction of treatment.

The study including 30 children has evaluated the efficacy and safety of use of tumor necrosis factor α blocker adalimumab (Humira ®, Abbott Laboratories Ltd, UK) for the treatment of patients with different variants of juvenile rheumatoid arthritis (JRA). The results confirm the efficacy and safety of adalimumab in the treatment of various forms of JRA. It was concluded that early administration of adalimumab allows to achieve the better control of disease activity, avoid the complications of glucocorticosteroid therapy and the formation of steroiddependence in JRA

The article presents data on the prevalence of one of the most common pain syndromes - back pain. The literary data on the mechanisms of formation of pain and ways to its elimination are proposed. The results of own authors research of use of one of the most popular cyclooxygenase-2 inhibitors - Movalis (meloxicam) - in 767 patients are represented. The results showed fairly stable positive effect of therapy, which led to a decrease in frequency, intensity and duration of acute back pain within two years of follow-up. The possibility of central action of the drug through the effect on «pain» memory is discussed.

The article presents the results of the program "Osteoscreening Russia" supported by the Russian Association for Osteoporosis (OP). Screening showed a high frequency of detection of risk factors for OP among residents of various regions of Russia aged 50 years and older. In addition, it was found that over 70% of examined persons have consumed less than half of the guideline daily amounts of calcium with food, that requires correction of the diet or the use of calcium in the form of pharmaceutical supplements (calcium and vitamin D), especially at the background of existing lower mineral bone density.